2026 Notice of Annual General Meeting
Released
Released
Announcement PDF
ATOMO DIAGNOSTICS LIMITED
ACN 142 925 684
Notice of Annual General Meeting
Explanatory Statement and Proxy Form
Date of Meeting:
Thursday, 5 November 2026
Time of Meeting:
10:00am (AEDT)
The meeting will be held by live webcast via:
Zoom webinar
The meeting will be held virtually via a webinar conferencing facility. If you are a shareholder who wishes to
attend and participate in the virtual meeting, please register in advance as per the instructions outlined in
this Notice of Meeting. Shareholders are strongly encouraged to lodge their completed proxy forms in
accordance with the instructions in this Notice of Meeting.
This Notice of Annual General Meeting and Explanatory Statement should be read in its entirety.
If shareholders are in doubt as to how they should vote, they should seek advice from their accountant,
solicitor or other professional advisor without delay.
ATOMO DIAGNOSTICS LIMITED
ACN 142 925 684
Registered office: Level 1, 3-5 George St. Leichhardt NSW 2040
NOTICE OF ANNUAL GENERAL MEETING
Notice is given that the Annual General Meeting (“AGM” or “Meeting”) of Members of Atomo Diagnostics Limited
(the “Company”) will be held by video-conferencing facility at 10:00am (AEDT) on Thursday, 5 November 2026.
The technology used to hold the Meeting virtually will provide Shareholders with a reasonable opportunity to ask
questions or make comments. Voting at the Meeting is occurring by way of poll rather than a show of hands.
Each person entitled to vote is to be given the opportunity to vote in real time, and this Notice of Meeting includes
information about how shareholders can participate in the Meeting. Shareholders attending virtually will be taken
for all purposes to be in attendance as if they were physically there.
Shareholders are encouraged to submit their proxies as early as possible and in any event prior to the cut-off for
proxy voting as set out in the Notice. To lodge your proxy, please follow the directions on your personalised proxy
form.
Shareholders who wish to participate in the AGM online may register in advance for the Meeting:
https://vistra.zoom.us/webinar/register/WN_CLGwUlGLSiWUuPGaVPjFZQ
When: Thursday, 5 November 2026 at 10:00am (AEDT)
Topic: Atomo Diagnostics Limited – 2026 Annual General Meeting
After registering, you will receive a confirmation email containing information about joining the Meeting. The
Company strongly recommends its Shareholders to lodge a direct proxy as soon as possible in advance of the
Meeting even if they are planning to attend the Meeting online.
The Company is happy to accept and answer questions submitted prior to the Meeting by email to the Company
Secretary Mathew Watkins, mathew.watkins@vistra.com. Where a written question is raised in respect to the key
management personnel (“KMP”) of the Company and/or the Resolutions to be considered at the Meeting, the
Company will address the relevant question during the course of the Meeting or by written response after the
Meeting (subject to the discretion of the Company not to respond to unreasonable and/or offensive questions).
Any Shareholder wishing to attend the AGM online should therefore monitor the Company’s website and its ASX
announcements for any updates about the AGM. If it becomes necessary or appropriate to make alternative
arrangement for the holding or conduct of the Meeting, the Company will make further information available
through the ASX website at www.asx.com.au (ASX: AT1) and on its website at
https://investors.atomodiagnostics.com/investor-centre/.
2
AGENDA
The Explanatory Statement and proxy form, which accompany and form part of this Notice, include defined terms
and describe in more detail the matters to be considered. Please consider this Notice, the Explanatory Statement
and the proxy form in their entirety.
ORDINARY BUSINESS
Receipt and Consideration of Financial Statements & Reports
To receive and consider the 2026 Annual Report of the Company and its controlled entities for the financial year
ended 30 June 2026, which includes the Financial Report, the Directors' Report and the Auditor's Report.
Note: Except for as set out in Resolution 1, there is no requirement for shareholders to approve these reports.
Accordingly, no resolution will be put to shareholders on this item of business.
Resolution 1: Adoption of Remuneration Report
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That for the purpose of section 250R(2) of the Corporations Act and for all other purposes, the Remuneration
Report (included in the Directors' report) for the financial year ended 30 June 2026 be adopted.”
Resolution 2: Re-election of Mr Patrick Cook as a Director of the Company
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purpose of Rule 20.6 of the Constitution and for all other purposes, Mr Patrick Cook who retires by
rotation as a Director in accordance with the Constitution of the Company, and who, being eligible, offers himself
for re-election, be re-elected as a Director of the Company.”
Resolution 3: Ratification of prior issue of 90,909,091 Ordinary Shares and 45,454,536 Options, as part of
the Placement
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders approve, ratify and confirm
the allotment and issue of 90,909,091 fully paid ordinary shares (“Shares”) in the Company on 8 April 2026 at an
issue price of $0.033 (3.3 cents) per Share and 45,454,536 free attaching unlisted options (“Options”) in relation
to the Placement to professional, sophisticated and other exempt investors as described in the Explanatory
Statement.”
Resolution 4: Ratification of prior issue of Broker Options to Joint Lead Managers
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 7.4 and for all other purposes, shareholders approve, ratify and confirm
the issue and allotment of 5,000,000 Broker Options (“Options”) in the Company to Joint Lead Managers, at a
exercise price of $0.045 (4.5 cents) per Option, as part consideration on the terms and conditions set out in the
Explanatory Statement.”
Resolution 5: Ratification of prior issue of 1,348,480 Ordinary Shares and 674,229 Options, as part of the
Share Purchase Plan (SPP)
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 7.4 and for all other purposes, Shareholders approve, ratify and confirm
the allotment and issue of 1,348,480 fully paid ordinary shares (“Shares”) in the Company on 15 May 2026 at an
issue price of $0.033 (3.3 cents) per Share and 674,229 free attaching unlisted options (“Options”) in relation to
the Share Purchase Plan (“SPP”) as described in the Explanatory Statement.”
3
Resolution 6: Approval of Employee Option Plan
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That for the purposes of ASX Listing Rule 7.2 Exception 13(b) and for all other purposes, approval is given for
the Company to issue Equity Securities under the Company’s Employee Option Plan as an exception to Listing
Rule 7.1 on the terms and conditions as set out or described in the Explanatory Statement which accompanies
and forms part of this Notice of Meeting.”
Resolution 7: Approval to Grant Options to Mr Patrick Cook (and/or his nominee(s))
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 1,400,000
Options in the Company to Mr Patrick Cook, (and/or his nominee(s)), Non-Executive Chair of the Company, on
the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting.”
Resolution 8: Approval to Grant Options to Mr Anthony May (and/or his nominee(s))
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 1,000,000
Options in the Company to Mr Anthony May (and/or his nominee(s)), Non-Executive Director of the Company, on
the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting.”
Resolution 9: Approval to Grant Options to Dr Cheri Walker (and/or her nominee(s))
To consider and, if thought fit, to pass the following resolution as an ordinary resolution:
“That, for the purposes of Listing Rule 10.14 and for all other purposes, approval be given to grant 700,000
Options in the Company to Dr Cheri Walker (and/or her nominee(s)), Interim Managing Director of the Company,
on the terms and conditions set out in the Explanatory Statement accompanying the Notice of Meeting.”
SPECIAL BUSINESS
Resolution 10: Approval of 10% Placement Facility
To consider and, if thought fit, pass the following resolution as a special resolution:
“That, pursuant to and in accordance with Listing Rule 7.1A and for all other purposes, shareholders approve the
issue of Equity Securities up to the equivalent of 10% of the Company’s fully paid ordinary issued capital (at the
time of the issue) calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and on the terms
and conditions in the Explanatory Statement.”
By the order of the Board
Mathew Watkins
Company Secretary
25 September 2026
4
Notes
1. Entire Notice: The details of the resolutions contained in the Explanatory Statement accompanying this Notice of Meeting should
be read together with, and form part of, this Notice of Meeting.
2. Record Date: The Company has determined that for the purposes of the Annual General Meeting, shares will be taken to be held
by the persons who are registered as holding the shares at 7.00pm (AEDT), 48 hours before the date of the AGM. Only those
persons will be entitled to vote at the AGM and transfers registered after that time will be disregarded in determining entitlements
to attend and vote at the AGM.
3. Proxies
a. Votes at the AGM may be given personally or by proxy, attorney or representative.
b. Each member has a right to appoint one or two proxies.
c. A proxy need not be a member of the Company.
d. If a member is a company it must execute under its common seal or otherwise in accordance with its constitution or the
Corporations Act.
e. Where a shareholder is entitled to cast two or more votes, the shareholder may appoint two proxies and may specify the
proportion or number of votes each proxy is appointed to exercise.
f. If a shareholder appoints two proxies, and the appointment does not specify the proportion or number of the
shareholder’s votes, each proxy may exercise half of the votes. If a shareholder appoints two proxies, neither proxy may
vote on a show of hands.
g. A proxy must be signed by the shareholder or his or her attorney who has not received any notice of revocation of the
authority. Proxies given by corporations must be signed in accordance with corporation’s constitution and Corporations
Act.
h. To be effective, proxy forms must be received by the Company’s share registry no later than 48 hours before the
commencement of the AGM, this is no later than 10:00am (AEDT) on Tuesday, 3 November 2026. Any proxy received
after that time will not be valid for the scheduled Meeting.
4. Corporate Representative
Any corporate shareholder who has appointed a person to act as its corporate representative at the Meeting should provide that
person with a certificate or letter executed in accordance with the Corporations Act authorising him or her to act as that company’s
representative. The authority may be sent to the Company and/or share registry in advance of the Meeting or handed in at the
Meeting when registering as a corporate representative.
5. Voting Exclusion Statement:
Resolution 1
In accordance with sections 250R(4) and 250BD(1) of the Corporations Act, a vote must not be cast (in any capacity), and the
Company will disregard any votes purported to be cast, on this Resolution by, or on behalf of, a member of the Key Management
Personnel (“KMP”), details of whose remuneration are included in the remuneration report, or a Closely Related Party of such a
member (either being a “KMP voter”), unless the KMP voter is casting a vote on behalf of a person who is not a KMP voting
(including as a proxy) and either:
a. the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
b. the KMP voter is by the Chair of the Meeting and the appointment of the Chair as proxy:
i. does not specify the way the proxy is to vote on the Resolution; and
ii. expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with
the remuneration of a member of the key KMP for the Company or the consolidated entity.
If you appoint the Chair as your proxy and you do not direct the Chair on how to vote, you will be expressly authorising the Chair to
exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the KMP
for the Company.
If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair will vote any
proxies which do not indicate on their proxy form the way the Chair must vote, in favour of the Resolution. In exceptional
circumstances, the Chair may change their voting intention on the Resolution, in which case an ASX announcement will be made.
Shareholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and
you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.
A further restriction also applies to KMP and their Closely Related Party voting undirected proxies on this Resolution – see
Restriction on KMPs voting undirected proxies below.
Resolution 2
There are no voting exclusions on this Resolution.
Resolutions 3 – 5
The Company will disregard any votes cast in favour of these Resolutions by or on behalf of any person, and any associates of that
person, who participated in the issue of securities participated in the issue of securities including Company’s Joint Lead Managers,
Alpine Capital Pty Ltd and GBA Capital Pty Ltd.
However, this does not apply to a vote cast in favour of the Resolution by:
5
(a) a person as a proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with directions given to
the proxy or attorney to vote on the Resolution in that way; or
(b) the Chair of the Meeting as proxy or attorney for a person who is entitled to vote on the Resolution, in accordance with a
direction given to the Chair to vote on the Resolution as the Chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not
an associate of a person excluded from voting, on the Resolution; and
ii. the holder votes on the Resolution in accordance with directions given by the beneficiary to the holder to vote in that
way.
Resolutions 6
The Company will disregard any votes cast in favour of this Resolution by any person eligible to participate in the Company’s
Employee Option Plan, and any of their associates.
However, this does not apply to a vote cast in favour of the resolution by:
(a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to
the proxy or attorney to vote on the resolution in that way; or
(b) the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction
given to the chair to vote on the resolution as the chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not
an associate of a person excluded from voting, on the resolution; and
ii. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that
way.
A vote must not be cast as proxy on this Resolution by a KMP voter. However, a KMP voter may cast a vote on behalf of a person
who is not a KMP voter if:
(a) the KMP voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution; or
(b) the KMP voter is by the Chair of the Meeting and the appointment of the Chair as proxy:
i. does not specify the way the proxy is to vote on the Resolution; and
ii. expressly authorises the Chair to exercise the proxy even if the Resolution is connected directly or indirectly with
the remuneration of a member of the key KMP for the Company or the consolidated entity.
If you appoint the Chair as your proxy and you do not direct the Chair on how to vote, you will be expressly authorising the Chair to
exercise the proxy even if the relevant Resolution is connected directly or indirectly with the remuneration of a member of the KMP
for the Company.
If the Chair of the Meeting is appointed as a proxy for a person who is permitted to vote on this Resolution, the Chair will vote any
proxies which do not indicate on their proxy form the way the Chair must vote, in favour of the Resolution. In exceptional
circumstances, the Chair may change their voting intention on the Resolution, in which case an ASX announcement will be made.
Shareholders may also choose to direct the Chair to vote against the Resolution or to abstain from voting.
If you purport to cast a vote other than as permitted above, that vote will be disregarded by the Company (as indicated above) and
you may be liable for breaching the voting restrictions that apply to you under the Corporations Act.
Resolutions 7 – 9
The Company will disregard any votes cast in favour of each of Resolutions 7 through to 9 (respectively and separately) by or on
behalf of
• Mr Patrick Cook, Mr Anthony May, Dr Cheri Walker or any person(s) who will obtain a material benefit as a result of the
proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity), or
• an associate of person referred to in the preceding paragraph.
However, this does not apply to a vote cast in favour of the resolution by:
(a) a person as a proxy or attorney for a person who is entitled to vote on the resolution, in accordance with directions given to
the proxy or attorney to vote on the resolution in that way; or
(b) the chair of the meeting as proxy or attorney for a person who is entitled to vote on the resolution, in accordance with a direction
given to the chair to vote on the resolution as the chair decides; or
(c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the
following conditions are met:
i. the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not
an associate of a person excluded from voting, on the resolution; and
ii. the holder votes on the resolution in accordance with directions given by the beneficiary to the holder to vote in that
way.
Furthermore, a vote must not be cast as proxy on any Resolutions 7, 8 and 9 by a member of the Key Management Personnel (as
defined by the Corporations Act) or a closely related party of Key Management Personnel.
Resolution 10
As at the date of despatch of this Notice, the Company does not have approval to make an issue of Equity Securities under Listing
Rule 7.1A.2 and, therefore, a voting exclusion statement on this Resolution is not required by Listing Rule 7.3A.7 as at that date.
6
This is a Special Resolution requiring at least 75% of the votes cast by Shareholders entitled to vote to be in favour of the Resolution
in order for it to pass.
6. Restriction on KMPs voting undirected proxies:
A vote must not be cast as proxy on Resolution 1 or Resolution 6 by a member of the KMP (as defined by the Corporations Act) or
a Closely Related Party of a KMP.
However, a person described above (a “Restricted Voter”) may cast a vote on behalf of a person who is not a Restricted Voter on
Resolution 1 or Resolution 6 as a proxy if:
(a) The Restricted Voter is appointed as a proxy by writing that specifies the way the proxy is to vote on the Resolution(s); or
(b) The Chair is the Restricted Voter and the written appointment of the Chair as proxy does not specify the way the proxy is to
vote on the Resolution(s) or expressly authorises the Chair to exercise the proxy even though the Resolution(s) is connected
directly or indirectly with the remuneration of a member of the KMP.
If you appoint the Chair as your proxy and you do not direct the Chair how to vote, you will be expressly authorising the Chair to
exercise the proxy even if the relevant Resolution(s) is connected directly or indirectly with the remuneration of a member of the
KMP for the Company.
7. Enquiries
Shareholders are invited to contact the Company Secretary on (03) 9692 7222 if they have any queries in respect of the matters
set out in these documents.
7
EXPLANATORY STATEMENT
Purpose of Information
This Explanatory Statement (“Statement”) accompanies and forms part of the Company’s Notice of Annual
General Meeting (“Notice”) for the 2026 Annual General Meeting (“Meeting”) will be held by video-conferencing
facility at 10.00am (AEDT) on Thursday, 5 November 2026.
The Notice incorporates, and should be read together, with this Statement.
Receipt and consideration of Accounts & Reports
A copy of the Annual Report for the financial year ended 30 June 2026 (which incorporates the Company's
financial report, reports of the Directors (including the Remuneration Report) and the auditors) the Company's
website https://investors.atomodiagnostics.com/investor-centre/?page=financial-reports or via the Company's
announcement platform on ASX. Alternatively, you may obtain a copy free of charge in hard copy form by
contacting the Company by phone at 02 9099 4750 and you may request that this occurs on a standing basis for
future years. There is no requirement for Shareholders to approve the Annual Report.
Shareholders will have the opportunity at the Meeting to ask questions about or make comments on the 2026
Financial Report, the Directors’ Report, and the Auditor’s Report. Questions for the Company’s auditors relating
to the conduct of the audit, preparation and contents of the audit report, accounting policies adopted by the
Company in relation to the preparation of its financial statements, and the independence of the auditors in relation
to the conduct of the audit, must be submitted no later than 5 business days before the Meeting to the Company
Secretary at the Company's registered office. The auditor will be invited to attend and answer questions about
the audit of the Company’s 2026 Annual Financial Statements.
ORDINARY BUSINESS
Resolution 1: Adoption of Remuneration Report
Background
Section 250R (2) of the Corporations Act requires that a resolution to adopt the Remuneration Report must be
put to the vote at the Annual General Meeting. The vote on this Resolution is advisory only and does not bind the
Directors or the Company.
The Remuneration Report is set out in the Directors’ Report in the Company’s 2026 Annual Report. The
Remuneration Report sets out the Company’s remuneration arrangements for the Directors and senior
management of the Company.
In accordance with section 250SA of the Corporations Act, shareholders will be provided with a reasonable
opportunity to ask questions concerning, or make comments on, the Remuneration Report at the AGM.
In accordance with Division 9 of Part 2G.2 of the Corporations Act, if twenty five (25%) per cent or more of votes
that are cast are voted against the adoption of the Remuneration Report at two consecutive Annual General
Meetings, shareholders will be required to vote at the second of those Annual General Meetings on a resolution
(a “spill resolution”) that another meeting be held within 90 days at which all of the Company’s Directors (other
than the Managing Director) must go up for re-election.
At its last annual general meeting, a Spill Resolution was put to shareholders, as a result of there having been
two consecutive Annual General Meetings (including the last annual general meeting) at which at least 25% of
the votes cast on the Remuneration Report resolution were cast against the Remuneration Report Resolution.
The Spill Resolution put to shareholders at the last annual general meeting was not passed by shareholders
therefore a Spill Resolution is not relevant for this Annual General Meeting.
The Directors will consider the outcome of the vote and comments made by Shareholders on the Remuneration
Report at the Meeting when reviewing the Company’s remuneration policies.
8
Board Recommendation
Noting that each Director has a personal interest in their own remuneration from the Company (as such interests
are described in the Remuneration Report) and, as described in the voting exclusions on this Resolution (set out
in the Notice of AGM), that each Director (or any Closely Related Party of a Director) is excluded from voting their
shares on this Resolution, the Directors encourages all eligible shareholders to cast their votes in favour of this
Resolution.
Voting Intention
The Chair intends to vote all undirected proxies in favour of this resolution.
Voting Exclusions
A voting exclusion statement for this resolution is set out in Note 5 and 6 above.
Resolution 2: Re-election of Mr Patrick Cook as a Director of the Company
Background
Clause 20.6 of the Constitution of the Company requires that at each annual general meeting one third of the
Directors (except for the managing director) shall retire from office by rotation. The Directors to retire in every
year shall be those who have been longest in office since their last election.
Mr Cook was appointed Non-executive Director on 2 May 2025. Mr Cook is an experienced Non-Executive
Director and Chair with over 35 years experience as a senior executive in medical devices & point-of-care
diagnostics sectors within various multinational, private and listed biotechnology companies. Currently serves as
Non-Executive Director at Workplace Drug Testing Australasia Ltd and as a Committee Member at Animal Ethics
Committee QUT. Previously served as Non- Executive Director & Chair at eWaste Connection Ltd, Board Member
at Prostate Cancer Foundation of Australia (Qld), a Fellow of the Australian Institute of Company Directors and
holds degrees in Science and Marketing.
The Company considers Mr Cook as an independent director for all purposes.
Board Recommendation
The Board (with Mr Cook abstaining in his capacity as a Director) recommends that shareholders vote in favour
of this Resolution as it considers that Mr Cook ’s qualifications, experience, skills, and expertise are appropriate
for the Board position and will enable him to act in the best interests of the Company and its shareholders.
Voting Intention
The Chair intends to vote all undirected proxies in favour of this Resolution.
Voting Exclusions
There are no voting exclusions on this Resolution.
Background to Resolutions 3 to 5
On 30 March 2026, the Company announced that it was undertaking a capital raising to raise up to approximately
$4.0 million, by way of Placement to raise $3.0 million (“Placement”) and Share Purchase Plan (“SPP”) to raise
up to 1.0 million (together known as “Capital Raising”).
On 8 April 2026, the Company issued 90,909,091 new fully paid ordinary shares (“Shares”) at an issue price of
$0.033 (3.3 cents) per share with 45,454,536 free attaching options, exercisable at $0.045 (4.5 cents) expiring
2.5 years from the date of issue, on the basis of one option for every two new shares subscribed for and issued
("Options").
9
The Placement was undertaken by the Company with Joint Lead Managers, Alpine Capital Pty Ltd and GBA
Capital Pty Ltd (“JLM’s”). One 8 April 2026, the JLM’s received 5,000,000 Broker Options issued on the same
terms as the Placement and SPP free attaching options.
On 15 May 2026, the Company issued 1,348,480 Shares and 674,229 Options (“SPP Securities”) to existing
shareholders, on the same terms as that of the placement participants. The SPP Securities were offered under a
Prospectus, the Company is not relying on ASX Listing Rule 7.2 (Exception 5) and therefore will seek approval
to ratify.
The Placement, SPP and associated resolutions are summarized below:
• Resolution 3: Ratification of prior issue of 90,909,091 Ordinary Shares and 45,454,536 Options, as
part of the Placement
• Resolution 4: Ratification of prior issue of Broker Options to Joint Lead Managers
• Resolution 5: Ratification of prior issue of 1,348,480 Ordinary Shares and 674,229 Options, as part of
the Share Purchase Plan (SPP)
Resolution 3: Ratification of prior issue of 90,909,091 Ordinary Shares and 45,454,536 Options, as part
of the Placement
Background
As noted above, the Company is seeking shareholder approval pursuant to ASX Listing Rule 7.4 to ratify the
issue of 90,909,091 Shares in the Company at an issue price of $0.033 (3.3 cents) per Share and 45,454,536
Options, on 8 April 2026 on the terms as announced on 30 March 2026 (“Placement Securities”).
The Shares and Options were issued w
Share your feedback
Discover